Pharmacokinetics of ABT-761 in several species
| Species (route2-a) | Bioavailability2-b | tmax | t½2-c | Cmax2-d |
|---|---|---|---|---|
| % | hr | hr | μmol | |
| Mouse (p.o.) (5)2-e | 100 | 1.5 | 3.62-f | 17.1 |
| Mouse (i.v.) (5) | 4.2 | |||
| Rat (p.o.) (4) | 60 | 1.5 | 3.02-f | 12.2 |
| Rat (i.v.) (4) | 3.6 | |||
| Guinea pig (p.o.) (4) | 90 | 5.0 | 10.42-f | 10.4 |
| Guinea pig (i.v.) (4) | 7.6 |
↵2-a Compound dosed by oral gavage in 0.2% HPMC at 4 mg/kg (mouse, rat and guinea pig) or intravenously in 20% DMSO, 40% ethanol and 40% saline or in 9% molecusol.
↵2-b Bioavailability from comparison of oral and intravenous studies.
↵2-c Intravenous half-life determined from the slope of the elimination curves.
↵2-d Maximum plasma concentration achieved.
↵2-e Number of animals is given within parentheses.
↵2-f Estimated oral half-life.